U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CVM GFI #259 (VICH GL58) Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

CVM GFI #259 (VICH GL58) Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV April 2020

Final
Docket Number:
FDA-2018-D-4662
Issued by:
Guidance Issuing Office
Center for Veterinary Medicine

The world can be divided into four climatic zones, I-IV, based on the prevailing annual climatic conditions and the guideline published by the World Health Organization.

This document is an annex to the VICH parent stability guidance, CVM Guidance for Industry (GFI) #73/VICH GL3(R), “Stability Testing of New Veterinary Drug Substances and Medicinal Products (Revision)” and provides guidance regarding the stability data package for a new veterinary drug substance and medicinal product to be included in a registration or application submitted within the regions in climatic zones III and IV.

The guidance seeks to exemplify the core stability data package for new veterinary drug substances and medicinal products, but leaves flexibility to encompass the variety of different practical situations that may be encountered due to specific scientific considerations and characteristics of the materials being evaluated.  Alternative approaches can be used when there are scientifically justifiable reasons.


Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2018-D-4662.

Questions?

Back to Top